ARVN
ARVN
Positions held
Your positionsARVN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 · Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
2026-09-15 · AdvanCell Appoints Sean Cassidy as Chief Financial Officer
2026-09-09 · Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
2026-09-03 · Arvinas to Participate in Upcoming Investor Conferences
2026-09-03 · Can KT-621 Mark a Turning Point for Kymera Therapeutics?
2026-09-01 · Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-11 · Arvinas (ARVN) Q2 2026 Earnings Call Transcript
2026-08-10 · Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
Price (daily)
Full chart · RSI · MACD · patterns